Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.
Revision as of 03:30, 14 May 2026 by MDElliottMD (talk | contribs) (Pharmacopedia: add <pharmaInteractions/>)
TCA, Antidepressant
Desipramine
Norpramin

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions10 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 normal metabolizer monitor CPIC Strong 70 / 100
CPIC rec 8093968 [Strong]: Initiate therapy with recommended starting dose CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2D6 ultrarapid metabolizer avoid FDA Label 35 / 100
CPIC rec 8093961 [Optional]: Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040] FDA labeling (Precautions)
Phenotype:CYP2D6 poor metabolizer avoid FDA Label 35 / 100
CPIC rec 8093977 [Optional]: Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040] FDA labeling (Precautions)
Phenotype:CYP2D6 intermediate metabolizer monitor CPIC B 20 / 100
CPIC rec 8093973 [Optional]: Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP2D6 substrate major Primary 80 / 100
FDA Drug Interactions Table: sensitive index substrate of CYP2D6.
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Quinidine pk raises via CYP2D6 Inferred 76 / 100
Quinidine inhibits CYP2D6 (inhibitor_strong, intensity 95); Desipramine is a substrate_major of CYP2D6 (intensity 80). Derived: Desipramine exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Fluoxetine pk raises via CYP2D6 Inferred 72 / 100
Fluoxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Desipramine is a substrate_major of CYP2D6 (intensity 80). Derived: Desipramine exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Paroxetine pk raises via CYP2D6 Inferred 72 / 100
Paroxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Desipramine is a substrate_major of CYP2D6 (intensity 80). Derived: Desipramine exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Bupropion pk raises via CYP2D6 Inferred 68 / 100
Bupropion inhibits CYP2D6 (inhibitor_strong, intensity 85); Desipramine is a substrate_major of CYP2D6 (intensity 80). Derived: Desipramine exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Mirabegron pk raises via CYP2D6 Inferred 44 / 100
Mirabegron inhibits CYP2D6 (inhibitor_moderate, intensity 55); Desipramine is a substrate_major of CYP2D6 (intensity 80). Derived: Desipramine exposure raised.
Inferred via Enzyme:CYP2D6 (exposure raised)

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
TCA, Antidepressant
Common uses
Pharmacy
Pharmacology
Purported mechanism
Selective norepinephrine reuptake inhibitor